09/04/2018 07:00:17

Rathbone Brothers Plc : Response to press speculation

Related content
04 Oct - 
Appointment of Group Finance Director
04 Oct - 
Director/PDMR Shareholding
01 Oct - 
Total voting rights

      

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

Rathbone Brothers Plc

Response to press speculation

 

The Board of Rathbone Brothers Plc ("Rathbones") notes the recent press speculation regarding Speirs & Jeffrey Limited ("Speirs & Jeffrey"). Rathbones regularly assesses various acquisition opportunities in line with its stated strategy and accordingly confirms that discussions between Rathbones and Speirs & Jeffrey in relation to a possible acquisition of Speirs & Jeffrey by Rathbones are taking place.

No binding offer has been made and there can be no certainty that any binding offer will be made nor that agreement will be reached with the Board and shareholders of Speirs & Jeffrey. A further announcement will be made if and when appropriate.

The person responsible for arranging this announcement on behalf of Rathbones is Ali Johnson, Company Secretary.

9 April 2018

For further information contact:

Rathbone Brothers Plc

Tel: 020 7399 0000

email: shelly.patel@rathbones.com

 

Philip Howell, Chief Executive

Paul Stockton, Finance Director 

Shelly Patel, Head of Investor Relations

Camarco

Tel:

020 3757 4984

email:

ed.gascoigne-pees@camarco.co.uk

 

Ed Gascoigne-Pees

Hazel Stevenson 

   

Rathbone Brothers Plc

Rathbone Brothers Plc ("Rathbones"), through its subsidiaries, is a leading provider of high-quality, personalised investment and wealth management services for private clients, charities and trustees. Our services include discretionary investment management, unit trusts, banking and loan services, financial planning, unitised portfolio services, and UK trust, legal, estate and tax advice.

Rathbones has over 1,100 staff in 15 UK locations and Jersey; its headquarters is 8 Finsbury Circus, London.

rathbones.com


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Rathbone Brothers Plc via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
2
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
3
JCDecaux: Update on JCDecaux's proposed acquisition of APN Outdoor in Australia
4
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
5
ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)

Related stock quotes

Rathbone Brothers PLC OR.. 2,278.00 -1.4% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 October 2018 01:08:44
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB7 - 2018-10-16 02:08:44 - 2018-10-16 01:08:44 - 1000 - Website: OKAY